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Abstract. – Breast cancer is the most com-
mon cancer in women. Multicentric gliomas are
uncommon lesions of the central nervous system
(CNS) with an unprecise rate of occurrence that
diffusely infiltrate large portions of the brain. High
grade astrocytoma is the most agressive form of
gliomas and often has a distinct neuroimaging
pattern with a poor prognosis.
We report a case of a 29-year-old woman pa-
tient with primary breast carcinoma and high
grade astrocytoma subsequently developed.
The woman was treated by mastectomy and
20 months post-diagnosis of the cancer she ex-
hibited a transient facial paralysis. Magnetic res-
onance imaging (MRI) revealed two cranial
masses suspicious of metastasis. A complete
tumor removal from the brain was performed. On
histological examination, this tumor was a high
grade astrocytoma.
Key Words:
Invasive breast carcinoma, Multicentric high grade
astrocytoma.
Introduction
Breast cancer is the most common cancer
(21%) among women and the second leading
cause of cancer deaths. Annual breast cancer
deaths are exceeded only by those from lung can-
cer1. On the contrary, brain tumors are relatively
rare and are found at autopsy with a prevalence
between 1 and 2%2.
Half of the newly discovered brain tumors are
metastatic lesions, and breast cancer appears to
be the second leading cause of brain metastases3.
Anaplastic astrocytoma and glioblastoma ac-
count for approximately 38% of primary brain
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tumors, meningiomas and other mesenchymal tu-
mors approximately for 27%4.
Malignant astrocytoma and high-grade astro-
cytoma may arise from a diffuse astrocytoma or
may arise de novo without indication of a less
malignant precursor5. Anaplastic astrocytomas
possess an intrinsic tendency to progress to
glioblastoma. The mean age at biopsy is approxi-
mately 41 years. This tumor primarily affects the
cerebral hemispheres. Chromosomal abnormali-
ties are nonspecific. There is a consistently ob-
served male predominance in glioblastoma and
anaplastic astrocytoma, with a male to female ra-
tio between 1.5 and 2.06-8.
According to the literature, the association be-
tween breast cancer and high grade astrocytoma
is not as common as the association between
breast cancer and other primary malignant tu-
mors or intracranial tumors as well as menin-
giomas9.
A prior history of meningioma is associated
with a higher incidence of ductal breast carcino-
mas10-12. Recently, Piccirilli et al.12 recently de-
scribed the occurrence of glioblastoma multi-
forme (GBM) in 11 Italian patients previously
treated for breast cancer.
An association between breast and brain can-
cers is possible, especially in the rare autosomal
dominant Li-Fraumeni syndrome13, but otherwise
such an association is rare.
We report here the case of a 29 year-old
woman previously diagnosed with ductal carci-
noma of breast and subsequently developed
anaplastic astrocytoma.
Case Report
A 29-year-old woman with a right primary
breast carcinoma (T1N0M0: stage IA) was re-
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Figure 1. Photomicrographs illustrating histologic analysis of the patient’s breast tumor. A, Right breast ductal carcinoma
(hematoxylin-eosin ×100). B, Immunohistochemical examination of the right breast cancer by progesterone receptor (PR)
×100. C, PR ×400.
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ferred to our hospital. She had no past or family
history of malignancies. The tumor size was 2
cm in diameter at the first consultation. As for
the diagnostic procedures, mammography (Al-
pha RT, Instrumentarium, Helsinki, Finland) re-
vealed an ill-defined, spiculated tumor shadow
with diffuse microcalcifications in the right
breast. An irregular hypoechoic-tumorous lesion
could be detected in the upper-outer quadrant of
the right breast by ultrasonography (Sonoline
G40 Ultrasound Unit, SiemensTM, Erlangen,
Germany). A modified radical mastectomy of
the right breast was carried out in december
2006. Histological examination revealed that
the right breast tumor was a predominantly in-
traductal carcinoma, histological grade 2, with
negative lymph node metastasis (0/14) (Figure
1). Estrogen receptor (ER) and progesterone re-
ceptor (PR) of this tumor was positive by im-
munohistochemistry. Whereas the size of the in-
vasive component was only 1 × 1 cm in diame-
ter (50%), the size of the intraductal component
was 1 × 1 cm in diameter (50%). Lymphatic in-
vasion by tumor cells was positive but vascular
invasion by tumor cells was negative. Weakly
positive HER-2 overexpression (Dako Japan,
Tokyo, Japan) by immunohistochemical stain-
ing were observed in this tumor. The patient was
received adjuvant chemotherapy with endoxan
and epirubicin followed by methotrexate and
fluorouracil.
A 2 cm diameter mass detected in liver by ab-
dominal ultrasonography suspected of liver he-
mangioma. No other metastatic lesion was de-
tected by abdominal ultrasonography and chest
X-ray. BoneX-ray of the skull revealed no abnor-
malities.
20 months after the diagnosis of breast cancer,
patient developed epilepsy,left lower limp and
right upper limp paresis. Magnetic resonance
imaging (MRI) of the brain demonstrated two le-
sions, including a 50 × 45 mm well circum-
scribed mildly heterogenous mass with faint con-
trast enhancement in superficial left frontopari-
etal region and another smaller (19 × 11 mm)
non – enhancing mass lesion with homogenous
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signal intensity in right frontal lobe suspicious
for metastatic disease associated with her breast
cancer (Figure 2). The patient underwent a cran-
iotomy and gross total resection of the larger
frontoparietal lobe lesion.
The tumor was firm and had a white color.
The postoperative course was smooth and the pa-
tient remained neurologically intact. No other
possible metastatic lesion could be determined
during a detailed survey of the systems.
Histopathologic analysis demonstrated a high-
grade glial neoplasm with moderate mitotic ac-
tivity, characteristic of high grade astrocytoma
(Figure 3) Immunohistochemically, tumor cells
showed glial fibrillary acidic protein (GFAP) and
Ki-67 positivity. The Ki-67 labeling index was 2-
3%.
Tumor markers (CEA, CA125) were within
the normal rangesand and CA 15-3 level was
above normal.
The patient received external beam radiation
to 5000 cGy with low-dose daily temozolomide
and dexamethasone. Following radiation, she
continued temozolomide for several weeks. The
patient was discharged and continued the oral use
of tamoxifen and phenytoin.
The patient is currently well 4 years after the
initial surgery for breast cancer.
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Figure 2. Precontrast Axial Brain MRI T1 (A) and T2 images (B), and axial (C) and coronal (D) post- gadolinium images
revealing a dominant lesion located in the left frontoparietal lobe, and a second smaller lesion located in the right frontal lobe.
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Her latest examination was performed in the
two months ago and she was still neurologically
intact with no evidence of recurrence on MRI, or
metastasis.
Discussion
It has been reported that breast cancer is the
second most common cause of intracranial
metastases14. A personal or family history of
breast cancer is not currently considered a risk
factor for developing malignant glial tumors
and there are only a few reports in the literature
about the association between breast cancer
and brain glial tumor15,16. In contrast, there are
several clinical reports on patients who have
had breast cancer and meningioma9.
Multiple tumors in the brain usually indicate
metastatic disease. Primary brain tumors are
typically seen in a single region, but some brain
tumors like lymphomas, multicentric glioblas-
tomas and gliomatosis cerebri can be multifocal.
Roughly one-third of CNS tumors are metastatic
lesions, one third are gliomas and one-third is of
non-glial origin.
Glioma is a non-specific term indicating that
the tumor originates from glial cells like astro-
cytes, oligodendrocytes, ependymal and choroid
plexus cells. Gliomas are the most common pri-
mary brain tumors, and about three quarters of
them are aggressive. The true frequency of
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Figure 3. Histopathological examination of the brain tumor. H+E staining, showing fragments of highly cellular astrocytic tu-
mor with areas of moderate nuclear atipia and numerous interspersed gemistocytes. ×10. (A) ×40 (B) and ×100 (C).
glioma in adults, as compared with the frequency
of other intracranial neoplasms, is uncertain be-
cause of the difficulty in identifying indolent tu-
mors, the frequency of which would be underes-
timated in epidemiologic and most autopsy stud-
ies. All the subtypes of glioma can present as
very slowly expanding, calcified masses. Howev-
er, consideration of this patient’s age and the lo-
cation of the mass, suggests the most likely sub-
type.
Astrocytomas are the most common subtypes
of glioma and are usually lobar in adults. Most
astrocytomas are high-grade tumors, producing
rapidly progressive neurologic deficits, but about
10 percent of them are low grade and can be
asymptomatic for years17. However, it is unusual
for symptoms to begin after the age of 40 years
and in nearly half the cases of low-grade astrocy-
toma, the tumor eventually becomes high grade18.
Astrocytomas tend to infiltrate the white matter
diffusely before showing evidence of cortical in-
volvement. Calcification is found on CT images
in only 15 to 20 percent of cases19.
Glioblastoma and anaplastic astrocytoma re-
spectively account for 54% and 8% of all gliomas
in adults20. Astrocytomas occur at any age, but
glioblastoma multiforme is mostly seen in older
people.
The median age at diagnosis of glioblastoma is
58 to 63 years of age, and it is 43 to 52 years of
age for anaplastic astrocytoma6,20.
All brain tumors manifest symptoms based up-
on a combination of the tumor size and location.
Astrocytomas have a tendency to become pro-
gressively anaplastic if left untreated. This trans-
formation may be heralded by a rapid clinical de-
terioration.
Multicentric gliomas are well-separated le-
sions, localized in different lobes or hemispheres,
which cannot be ascribed to dissemination
through commissural pathways, cerebrospinal-
fluid (CSF), blood or local extension. Despite of
advances in neuroradiological techniques, in case
of multicentric cerebral lesions, differential diag-
nosis may require cerebral biopsy21-23.
Multicentric gliomas are uncommon lesions
of the central nervous system with an unprecise
rate of occurrence that diffusely infiltrate large
portions of brain. Various incidences ranging
from 2.3 to 9%24-25 have been reported. Radio-
logical features separate this group of brain tu-
mours and patients have a very short life ex-
pectancy even after surgical excision, radiothera-
py and chemotherapy.
Multicentric gliomas are fascinating lesions
of the brain. Making the differential diagnosis
and choosing the management strategy are the
main difficulties encountered with this rare enti-
ty. Multiple cerebral masses should be thor-
oughly evaluated and not always presumed to
be of metastatic origin26. Although multicentric
gliomas can mimic metastatic diseases, the treat-
ment of these two lesions is considerably differ-
ent with respect to adjuvant radiotherapy and
chemotherapy27-30.
Furthermore,multicentric glioma associated
with other primary cancers is extremely rare. To
date, reports have been limited to patients with
prostate, lung or colorectal cancers31. To our
knowledge, multicentric anaplastic astrocytoma
have not yet been described in the setting of
breast cancer. Anaplastic astrocytoma rarely oc-
curs in the presence of other primary tumors in
the general population. Until recently, only iso-
lated reports describing one or two patients have
documented glioblastomas that develop in pa-
tients with a previous history of breast can-
cer17,32-34.
A small proportion (less than 5%) of persons
with malignant astrocytoma has a definite or sus-
pected hereditary predisposition. High grade as-
trocytomas are associated with several hereditary
tumor disorders that also predispose toward the
development of breast cancer, including Li-Frau-
meni and Cowden syndromes. Malignant astro-
cytomas occur in approximately 10% of persons
with Li-Fraumeni syndrome, an autosomal domi-
nant disorder of susceptibility to a specific group
of tumors, including breast carcinoma, osteosar-
coma, soft tissue sarcomas, adrenocortical carci-
noma, leukemia, and brain tumors13,35. Pene-
trance is approximately 50% by 30 years of age
and 90% by 60 years of age. Affected individuals
may have multiple primary tumors. The vast ma-
jority of gliomas associated with Li-Fraumeni
syndrome occur prior to 40 years of age. A
germline mutation in the p53 gene located on
chromosome band 17p13, which encodes a nu-
clear transcription factor that regulates DNA re-
pair processes and the cell cycle is present in af-
fected persons from approximately 80% of fami-
lies with “classic” Li-Fraumeni syndrome36.
Conversely, Cowden syndrome results most
commonly from a mutation in the PTEN tumor
suppressor gene on chromosome band 10q2337.
The PTEN gene encodes a protein that inhibits
the PI3K signaling pathway required for regulat-
ing cell growth and survival, and thereby pro-
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motes cell death. PTEN inactivation, as seen in
Cowden syndrome, predisposes affected individ-
uals to breast and thyroid carcinomas as well as
mucocutaneous hamartomas. Similar genetic mu-
tations have been found in malignant astrocy-
tomas, glioblastomas, meningiomas, and medul-
loblastomas38,39. While the prevalence of these
hereditary genetic syndromes is extremely low,
somatic mutations in p53 and PTEN have been
demonstrated in several human cancers and are
likely to play an important role in the pathogene-
sis of a variety of tumors, including breast cancer
and high grade astrocytoma.
Hormonal sensitivity and steroid receptor
modulation may also serve as a common link in
the transformation, growth, and severity of
breast and glial tumors. Epidemiologic data
from the United States and Europe demonstrate
that the incidence of more malignant gliomas,
including anaplastic astrocytoma and GBM, is
approximately 1.5 times higher in males than
females8,40.
Furthermore, McKinley et al.40 reported that
the protective effects of gender peak at peri-
menopausal ages and diminish when women
reach postmenopausal ages. In animal studies, fe-
male nude mice implanted with human GBM
lines exhibit a survival advantage over males and
ovariectomized females undergoing similar treat-
ment. Estrogen replacement can reverse the ef-
fects of ovariectomy, suggesting that estrogen
may be largely responsible for the observed sur-
vival advantage in females41. Interestingly, higher
estrogen levels, a known risk factor for develop-
ing breast cancer, may protect against developing
high grade astrocytoma. In contrast, while prog-
esterone has no observed effect on survival in an-
imals42, a correlation between the presence of
progesterone receptors and more aggressive
gliomas, including anaplastic astrocytomas and
GBMs, has been observed in histologic studies42.
These observations suggest that regulation of
hormonal signaling may contribute to the patho-
genesis of breast and glial tumors.
The pathogenesis of multiple primary neo-
plasms is unknown. While extrinsic factors such
as environmental effects including irradiation or
chemical exposure to the host genome might be
important for heterochronous multiple primary
neoplasms, intrinsic factors, age, immunity or
genetic factors (for example, the rare autosomal
dominant Li-Fraumeni syndrome) have been pro-
posed as possible mechanisms in the occurrence
of multiple primary neoplasms43-44.
The relationship between sex steroid receptors
and the pathogenesis and/or treatment of either
breast cancer and prostatic carcinoma has previ-
ously been shown, and so in recent years45, there
has been increasing interest in the role of these
receptors in brain tumors.
Progesterone receptors in astrocytic tumors
were found to correlate with histologic grade and
to participate in the growth of these tumors and
tumor angiogenesis46.
Androgen and glucocorticoid receptor mRNAs
were detected in all astrocytic neoplasms. Prog-
esterone receptor mRNA was observed more fre-
quently in high grade gliomas than in low-grade
gliomas47. Normal astrocytes were consistently
negative for estrogen and progesterone receptors.
The majority of glioma cases were negative for
estrogen receptors while strong progesterone re-
ceptor nuclear immunopositivity was observed in
59% of glioblastomas, 45% of anaplastic astrocy-
tomas and 8% of low-grade astrocytomas42.
On the other hand, the antiestrogen tamoxifen
has been found to be effective in decreasing
glioblastoma cell proliferation48. Thus, the ex-
pression of estrogen receptor in U138MG
glioblastoma cells was successfully demonstrat-
ed49. These findings might raise the question of
whether the mechanism underlying this effect of
tamoxifen works through the estrogen receptors
of astrocytes. Khalid et al.50 showed that an es-
trogen receptor-related antigen (ER-D5) was
observed in the microvascular endothelial pro-
liferations and in tumor blood vessels, suggest-
ing its participation in the growth of the gliomas
and tumor angiogenesis. Tamoxifen probably
decreases cell proliferation through its effect on
this antigen.
We studied estrogen and progesterone recep-
tors on both pathologic slides of our patient.
However, neither estrogen nor progesterone re-
ceptor immunoreactivity were positive in high
grade astrocytoma, whereas the breast cancer
cells were positive for estrogen and progesterone
receptors. She still uses tamoxifen predominantly
for her breast cancer and no recurrence has been
detected at either site to date.
We failed to demonstrate a common hormonal
or oncogenetic basis for the neoplastic growth of
these 2 associate diverse primary malignancies in
our patient. Further investigations including mu-
tational analysis in such patients with mutiple
primary neoplasms may help to explore the ge-
netic and epigenetic factors influencing carcino-
genesis.
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